Oxford spinout Vaccitech, which developed the technology underlying the university’s covid vaccine, has filed for an offering on the Nasdaq Global Market.
Vaccitech, a UK-based developer of vaccines for infectious diseases and cancer spun out of University of Oxford, filed for an initial public offering in the US on Friday.
Financial terms have not yet been set and Vaccitech has used a placeholder $100m target in its draft prospectus. The spinout is looking to list on the Nasdaq Global Market and is seeking a valuation of around $700m, according to the Wall Street Journal.
Founded in 2016, Vaccitech originally…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
